{"status": "ok", "totalResults": 447, "articles": [{"source": {"id": "techcrunch", "name": "TechCrunch"}, "author": "Kate Clark", "title": "Indigo raises $250M, launches marketplace to help farmers get paid for quality grain", "description": "Indigo, the startup bringing algorithms and machine learning to the agricultural industry, has raised a $250 million Series E, bringing its total raised to $650 million. The funding values the company at $3.5 billion, according to a source familiar with the d\u2026", "url": "http://techcrunch.com/2018/09/18/indigo-raises-250m-launches-marketplace-to-help-farmers-get-paid-for-quality-grain/", "urlToImage": "https://techcrunch.com/wp-content/uploads/2018/09/Indigo_Wheat1.jpeg?w=600", "publishedAt": "2018-09-18T13:00:15Z", "content": "Indigo, the startup bringing algorithms and machine learning to the agricultural industry, has raised a $250 million Series E, bringing its total raised to $650 million. The funding values the company at $3.5 billion, according to a source familiar with the d\u2026 [+2449 chars]"}, {"source": {"id": "business-insider", "name": "Business Insider"}, "author": "Lydia Ramsey and Charlotte Hu", "title": "The Trump administration's top health official isn't counting on pharma to bring down drug prices", "description": "Health and Human Services Secretary Alex Azar isn't counting on pharmaceutical companies to do the right thing when it comes to drug prices. \"I'm not counting on their altruism or their cooperation,\" Azar said at the Financial Times' Pharma Pricing Summit on \u2026", "url": "https://www.businessinsider.com/hhs-secretary-alex-azar-on-drug-pricing-2018-9", "urlToImage": "https://amp.businessinsider.com/images/5a1ee1183dbef484008b8f22-2732-1366.jpg", "publishedAt": "2018-09-13T14:34:06Z", "content": "Department of Health and Human Services Secretary Alex Azar isn't banking on the pharmaceutical industry to fix the rising cost of prescription drugs in the US. \"I'm not counting on their altruism or their cooperation,\" Azar said at the Financial Times' Pharm\u2026 [+1364 chars]"}, {"source": {"id": "techcrunch", "name": "TechCrunch"}, "author": "John Biggs", "title": "Meet the startups in the latest Alchemist class", "description": "Alchemist is the Valley\u2019s premiere enterprise accelerator and every season they feature a group of promising startups. They are also trying something new this year: they\u2019re putting a reserve button next to each company, allowing angels to express their intere\u2026", "url": "http://techcrunch.com/2018/09/20/meet-the-startups-in-the-latest-alchemist-class/", "urlToImage": "https://techcrunch.com/wp-content/uploads/2018/09/image151.png?w=653", "publishedAt": "2018-09-20T17:30:10Z", "content": "Alchemist is the Valley\u2019s premiere enterprise accelerator and every season they feature a group of promising startups. They are also trying something new this year: they\u2019re putting a reserve button next to each company, allowing angels to express their intere\u2026 [+10659 chars]"}, {"source": {"id": null, "name": "Fool.com"}, "author": "newsfeedback@fool.com (George Budwell)", "title": "Why Exact Sciences Corporation Stock Rocketed Higher in August", "description": "Exact Sciences' stock got a major boost from a partnering deal with pharma titan Pfizer last month.", "url": "https://www.fool.com/investing/2018/09/07/why-exact-sciences-corporation-stock-rocketed-high.aspx", "urlToImage": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F493775%2Frocketman.jpg&h=630&w=1200&op=resize", "publishedAt": "2018-09-07T10:00:00Z", "content": "What happened Exact Sciences ( NASDAQ:EXAS ), a mid-cap cancer diagnostic company, saw its shares gain a healthy 26.7% last month, according to data from S&amp;P Global Market Intelligence. The spark? Exact Sciences' shares powered higher in response to a co-\u2026 [+1929 chars]"}, {"source": {"id": null, "name": "Fool.com"}, "author": "newsfeedback@fool.com (Keith Speights)", "title": "3 Top Big Pharma Stocks to Buy Now", "description": "Great dividends and great growth prospects make these big pharma stocks great picks for long-term investors.", "url": "https://www.fool.com/investing/2018/09/06/3-top-big-pharma-stocks-to-buy-now.aspx", "urlToImage": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F493451%2Fpharmaceutical-research.jpg&h=630&w=1200&op=resize", "publishedAt": "2018-09-06T10:30:00Z", "content": "Some people stick the word \"big\" in front of an industry name in an effort to disparage the largest players in that particular market. When I use the term \"big pharma,\" though, I'm not intending to be derogatory. My use of the label is to simply refer to the \u2026 [+4543 chars]"}, {"source": {"id": null, "name": "Entrepreneur.com"}, "author": "Isa Watson", "title": "Not Your Parents' Career Development", "description": "In today's world, professional success doesn't mean what it used to.", "url": "https://www.entrepreneur.com/article/319624", "urlToImage": "https://assets.entrepreneur.com/content/3x2/2000/20180919182539-GettyImages-661789569.jpeg", "publishedAt": "2018-09-20T13:30:00Z", "content": "September 20, 2018 6 min read Opinions expressed by Entrepreneur contributors are their own. For my parents, a career meant one thing: progressing through the ranks at a single company, climbing a corporate ladder where growth could be measured through regula\u2026 [+5785 chars]"}, {"source": {"id": "the-economist", "name": "The Economist"}, "author": null, "title": "Business this week", "description": "The Trump administration intensified its trade war with China, threatening to impose tariffs on a further $200bn-worth of goods, including tuna, chemicals and handbags.", "url": "https://www.economist.com/the-world-this-week/2018/07/12/business-this-week", "urlToImage": "/assets/the-economist-logo.png", "publishedAt": "2018-09-20T14:46:47Z", "content": "The Trump administration intensified its trade war with China, threatening to impose tariffs on a further $200bn-worth of goods, including tuna, chemicals and handbags. This came a few days after America fired its first salvo, levying duties on $34bn-worth of\u2026 [+4466 chars]"}, {"source": {"id": "the-economist", "name": "The Economist"}, "author": null, "title": "Business this week", "description": "The  IMF warned that the tariffs on imports threatened by both President Donald Trump and his trading partners could lower the annual growth rate of the global economy by 0.5 percentage points by 2020. The fund left its forecasts for global economic growth in\u2026", "url": "https://www.economist.com/the-world-this-week/2018/07/19/business-this-week", "urlToImage": "https://cdn.static-economist.com/sites/default/files/images/print-edition/20180721_WWP004_0.jpg", "publishedAt": "2018-09-20T14:46:47Z", "content": "The IMF warned that the tariffs on imports threatened by both President Donald Trump and his trading partners could lower the annual growth rate of the global economy by 0.5 percentage points by 2020. The fund left its forecasts for global economic growth in \u2026 [+4282 chars]"}, {"source": {"id": "bloomberg", "name": "Bloomberg"}, "author": null, "title": "Pfizer to Idle Plants in North Carolina With Hurricane Florence Approaching", "description": null, "url": "https://www.bloomberg.com/tosv2.html?vid=&uuid=ec67c3a0-b5ed-11e8-a686-d35d83610e7e&url=L25ld3MvYXJ0aWNsZXMvMjAxOC0wOS0xMS9wZml6ZXItdG8taWRsZS1wbGFudHMtaW4tbm9ydGgtY2Fyb2xpbmEtYXMtaHVycmljYW5lLWFwcHJvYWNoZXM=", "urlToImage": null, "publishedAt": "2018-09-11T17:07:37Z", "content": "Your usage has been flagged as a violation of our terms of service. For inquiries related to this message please contact support. For sales inquiries, please visit http://www.bloomberg.com/professional/request-demo If you believe this to be in error, please c\u2026 [+280 chars]"}, {"source": {"id": null, "name": "Forbes.com"}, "author": "Trefis Team, Contributor, Trefis Team, Contributor https://www.forbes.com/sites/greatspeculations/people/trefis/", "title": "A Look At Pfizer's Business And Outlook", "description": "Pfizer (NYSE:PFE) generates its revenues from its Oncology, Cardiovascular, Anti-Infective, Alimentary &amp;Metabolism, Neuroscience, Immunology drugs, along with its Legacy Pharma, Consumer, Biosimilar &amp; Other segment. Legacy Pharma, Consumer, Biosimilar\u2026", "url": "https://www.forbes.com/sites/greatspeculations/2018/09/10/a-look-at-pfizers-business-and-outlook/", "urlToImage": "https://thumbor.forbes.com/thumbor/600x315/https%3A%2F%2Fblogs-images.forbes.com%2Fthumbnails%2Fblog_25%2Fpt_25_188249_o.jpg%3Ft%3D1536604325", "publishedAt": "2018-09-10T18:32:00Z", "content": "Share to facebook Share to twitter Share to linkedin The Pfizer company logo is photographed at Pfizer Inc. headquarters, in New York, Monday, Dec. 4, 2017. (AP Photo/Richard Drew) Pfizer (NYSE:PFE) generates its revenues from its Oncology, Cardiovascular, An\u2026 [+9107 chars]"}, {"source": {"id": null, "name": "Marketwatch.com"}, "author": "Philip van Doorn", "title": "Deep Dive: These Dow Jones Industrial Average stocks have been left behind as the index hits a record", "description": "The benchmark finally tops the record it made in January.", "url": "https://www.marketwatch.com/story/these-dow-jones-industrial-average-stocks-have-been-left-behind-as-the-index-hits-a-record-2018-09-20", "urlToImage": "http://s.marketwatch.com/public/resources/MWimages/MW-GQ437_MCDP_2_ZG_20180920161117.jpg", "publishedAt": "2018-09-20T20:42:00Z", "content": "The Dow Jones Industrial Average DJIA, +0.95% rose to an intraday high Thursday, closing with a 1% gain. The S&amp;P 500 Index SPX, +0.78% was up 0.8% after setting another intraday record, following the latest round of good economic news. Bloomberg said its \u2026 [+2537 chars]"}, {"source": {"id": null, "name": "Yahoo.com"}, "author": null, "title": "Why Exact Sciences Corporation Stock Rocketed Higher in August", "description": "Exact Sciences' stock got a major boost from a partnering deal with pharma titan Pfizer last month.", "url": "https://finance.yahoo.com/news/why-exact-sciences-corporation-stock-100000965.html", "urlToImage": "https://s.yimg.com/uu/api/res/1.2/cuXO7YplZxOVKts6hNDIHw--~B/dz0wO3NtPTE7YXBwaWQ9eXRhY2h5b24-/http://media.zenfs.com/en-US/homerun/motleyfool.com/e4f07b38fce926e7eda0457056f7069a", "publishedAt": "2018-09-07T10:00:00Z", "content": "What happened Exact Sciences (NASDAQ: EXAS), a mid-cap cancer diagnostic company, saw its shares gain a healthy 26.7% last month, according to data from S&amp;P Global Market Intelligence. The spark? Exact Sciences' shares powered higher in response to a co-m\u2026 [+2147 chars]"}, {"source": {"id": null, "name": "Fool.com"}, "author": "newsfeedback@fool.com (Keith Speights)", "title": "Is Bristol-Myers Squibb Company a Buy?", "description": "This big pharma stock has some baggage, but it also claims two fast-growing blockbusters.", "url": "https://www.fool.com/investing/2018/09/09/is-bristol-myers-squibb-company-a-buy.aspx", "urlToImage": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F493827%2Fpills-foming-question-mark.jpg&h=630&w=1200&op=resize", "publishedAt": "2018-09-09T10:31:00Z", "content": "Bristol-Myers Squibb ( NYSE:BMY ) stock has underperformed the S&amp;P 500 index so far this year. It's also trailed well behind most of its peers, but it could be worse. Earlier in 2018, Bristol-Myers Squibb (BMS) was down 17%; now the stock has climbed back\u2026 [+3494 chars]"}, {"source": {"id": null, "name": "Seekingalpha.com"}, "author": "First Genesis Consulting", "title": "Pfizer And Conatus: Emricasan And NASH", "description": "Pfizer has proven itself to be a pioneer of therapeutics for HIV infection, autoimmune, cardiovascular and gastrointestinal diseases as well as hematological an", "url": "https://seekingalpha.com/article/4207139-pfizer-conatus-emricasan-nash", "urlToImage": "https://static2.seekingalpha.com/images/marketing_images/numbers_words_signs/signs/analysis.jpeg", "publishedAt": "2018-09-19T13:44:12Z", "content": "Money won't create success, the freedom to make it will - Nelson Mandela Investment Thesis Pfizer Inc. ( PFE ), a large-cap ($251B) multi-billion global biopharmaceutical company, gained pharmaceutical celebrity status when sildenafil citrate marketed globall\u2026 [+17394 chars]"}, {"source": {"id": null, "name": "Yahoo.com"}, "author": null, "title": "Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know", "description": "Pfizer (PFE) closed at $42.97 in the latest trading session, marking a +0.34% move from the prior day.", "url": "https://finance.yahoo.com/news/pfizer-pfe-outpaces-stock-market-214509813.html", "urlToImage": "https://s.yimg.com/uu/api/res/1.2/1MpaQeAGbKW4njUAW3XfGw--~B/aD00MjE7dz02MzU7c209MTthcHBpZD15dGFjaHlvbg--/http://media.zenfs.com/en-US/homerun/zacks.com/1154d43aaeb65735a640003549116295", "publishedAt": "2018-09-14T21:45:09Z", "content": "In the latest trading session, Pfizer (PFE) closed at $42.97, marking a +0.34% move from the previous day. This change outpaced the S&amp;P 500's 0.03% gain on the day. At the same time, the Dow added 0.03%, and the tech-heavy Nasdaq lost 0.05%. Coming into t\u2026 [+2831 chars]"}, {"source": {"id": null, "name": "Nejm.org"}, "author": "Kim Papp, Kenneth Gordon, Diamant Tha\u00e7i, Akimichi Morita, Melinda Gooderham, Peter Foley, Ihab G. Girgis, Sudeep Kundu, Subhashis Banerjee", "title": "Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis", "description": "Original Article from The New England Journal of Medicine \u2014 Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1806382", "urlToImage": "https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/0/nejm.ahead-of-print/nejmoa1806382/20180907/images/img_small/nejmoa1806382_f1.jpeg", "publishedAt": "2018-09-12T06:00:02Z", "content": "Supported by Bristol-Myers Squibb. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. Dr. Papp reports receiving grant support, consulting fees, advisory board fees, and fees for serving on a speakers\u2019 burea\u2026 [+4079 chars]"}, {"source": {"id": null, "name": "Yahoo.com"}, "author": null, "title": "Lilly, Teva, Pfizer & Others Await FDA Decisions in September", "description": "FDA grants approval to 34 new treatments this year so far.", "url": "https://finance.yahoo.com/news/lilly-teva-pfizer-others-await-125812067.html", "urlToImage": "https://s.yimg.com/uu/api/res/1.2/EyZmh1klWYX.2_4cspNDgQ--~B/aD00MTM7dz02MjA7c209MTthcHBpZD15dGFjaHlvbg--/http://media.zenfs.com/en-US/homerun/zacks.com/1c294b9de375a124a76eae049179f11e", "publishedAt": "2018-09-07T12:58:12Z", "content": "Like 2017, 2018 is turning out to be a pretty good one for pharma and biotech stocks as far as FDA decisions are concerned. The regulatory body approved 34 novel drugs till August. Last year, the FDA had given nod to 31 new drugs till August and approved 46 d\u2026 [+4154 chars]"}, {"source": {"id": null, "name": "Forbes.com"}, "author": "John Dorfman, Contributor, John Dorfman, Contributor https://www.forbes.com/sites/johndorfman/", "title": "Apple, Berkshire, Pfizer And 17 Other Large-Cap Buy And Sell Recommendations", "description": "Many investors favor large-caps. Here are recommendations on the 20 largest U.S. stocks..", "url": "https://www.forbes.com/sites/johndorfman/2018/09/17/apple-berkshire-pfizer-and-17-other-large-cap-buy-and-sell-recommendations/", "urlToImage": "https://thumbor.forbes.com/thumbor/600x315/https%3A%2F%2Fspecials-images.forbesimg.com%2Fdam%2Fimageserve%2Fa4969b25b24e467aa4db4387435f0b88%2F960x0.jpg%3Ffit%3Dscale", "publishedAt": "2018-09-17T14:27:00Z", "content": "Share to facebook Share to twitter Share to linkedin The iPhone XS (left) and XS Max (AP Photo/Marcio Jose Sanchez) My bread and butter are small-cap and mid-cap stocks. But many people stick to the largest stocks, so once a year I offer my buy and sell recom\u2026 [+9972 chars]"}, {"source": {"id": "usa-today", "name": "USA Today"}, "author": "The Center for Public Integrity, Sanya Mansoor, Liz Essley Whyte and Joe Yerardi, The Center for Public Integrity", "title": "Why corporations are pouring millions into sure-bet governor races", "description": "Why are companies giving millions to governors who may cruise to easy victory in November? Experts say it's likely an effort to court power", "url": "https://www.usatoday.com/story/news/politics/elections/2018/09/21/8-governors-use-campaign-money-shore-up-power-ahead-likely-wins/1367115002/?utm_source=google&utm_medium=amp&utm_campaign=speakable", "urlToImage": "https://www.gannett-cdn.com/-mm-/991bc3483005d7cdd0c348f3f7a3ef5003c4765e/c=0-133-512-422/local/-/media/2018/01/31/DetroitFreeP/DetroitFreePress/636529970940449010-election-generic.jpg?width=3200&height=1680&fit=crop", "publishedAt": "2018-09-21T09:00:08Z", "content": "Voters in 36 states will elect governors this November. Seven of the eight safe governors made it through their primaries with comfortable margins. But that hasn\u2019t slowed down their pace of fundraising. (Photo: Detroit Free Press) The multimillionaire governo\u2026 [+12477 chars]"}, {"source": {"id": null, "name": "Yahoo.com"}, "author": null, "title": "Pfizer's Skin Disease Drug Gets Breakthrough Therapy Status", "description": "Pfizer's (PFE) investigational oral JAK3 inhibitor PF-06651600 gets Breakthrough Therapy designation from the FDA for alopecia areata.", "url": "https://finance.yahoo.com/news/pfizer-apos-skin-disease-drug-145702447.html", "urlToImage": "https://s.yimg.com/uu/api/res/1.2/RcSGEOiRo4N.qL406x4Pog--~B/dz0wO3NtPTE7YXBwaWQ9eXRhY2h5b24-/http://media.zenfs.com/en-US/homerun/zacks.com/df5ad064f24e5502d8d1fb68bd8dc90d", "publishedAt": "2018-09-06T14:57:02Z", "content": "Pfizer, Inc. PFE announced that it has received Breakthrough Therapy designation for its pipeline candidate, PF-06651600 from the FDA. The candidate is being developed for alopecia areata, a chronic autoimmune skin disease that causes hair loss on the scalp, \u2026 [+3625 chars]"}]}